FibroGen Showcases Clinical Breakthroughs in Cancer Therapy at ASCO 2024 and Upcoming KOL Investor Event’
SAN FRANCISCO, May 23, 2024’ - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company committed to pioneering therapeutic advancements for serious unmet medical needs, is celebrating a significant milestone with the announcement of positive interim data from the dose escalation portion of the Phase 1b/2 study of FG-3246 (FOR46). This study is conducted by the University of California San Francisco and is designed to evaluate the efficacy of FG-3246, a potential first-in-class anti-CD46 antibody drug conjugate (ADC) containing an MMAE payload, in combination with enzalutamide in patients suffering from metastatic castration-resistant prostate cancer (mCRPC).
Presented at the prestigious 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, these imminent findings shed light on the auspicious potential of FG-3246 in transforming the therapeutic landscape for mCRPC. Prostate cancer remains a formidable adversary, particularly in its metastatic castration-resistant form, which is often refractory to conventional treatment modalities. The combination of the targeted anti-CD46 ADC FG-3246 with enzalutamide, a well-established androgen receptor inhibitor, marks a pioneering approach in tackling this insidious disease. The dose escalation phase has demonstrated promising safety and efficacy profiles, paving the way for the continuation into the expansion phase of the clinical trial.
FibroGen’s dedication to advancing cancer therapeutics does not end here. The company has also revealed plans to host Part I of a Virtual Key Opinion Leader (KOL) investor event series on February 13, 2024, focusing on its Pamrevlumab clinical program targeting pancreatic cancer. The virtual event is scheduled for 10:30 AM ET and will provide a platform for esteemed experts to delve into the significant advancements made in the development of Pamrevlumab.
For those interested in partaking in this insightful event, registration details can be accessed via the provided link click here(https://www.globenewswire.com/Tracker’data=NGz4K8Jnu1qZ3jzoFrXUIUqkbLOeR1mpv6517wMlv3Ne-ItAPvzMEonF5goAWJBJ0sXpCeE1auXMlxT69JzRe6P9q7Va0fwUDptBO8pBBSI=). This series underscores FibroGen’s unwavering commitment to transparency and communication with the investment community, alongside its drive to elevate cancer treatment paradigms through innovative clinical research.
About FibroGen, Inc.’
FibroGen, Inc. is a globally recognized biopharmaceutical company focused on discovering, developing, and commercializing novel therapies to treat serious unmet needs. Through its robust research and development pipeline, FibroGen aims to transform patient care by bringing groundbreaking therapies to market.
For additional information, please visit FibroGen’s website or contact their investor relations department.
Conclusion’
The dual announcements underscored by the positive interim results of FG-3246 combined with enzalutamide and the forthcoming KOL investor event highlight FibroGen’s pivotal role in advancing oncological research and therapeutic interventions. With an unwavering commitment to innovation and patient-centric approaches, FibroGen continues to lead the charge in combating some of the most challenging cancer types, thereby paving the way for a hopeful future in cancer treatment.
Comments